Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Completed · Phase 1/Phase 2
Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm
In brief
RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to cancer cells and not harm normal cells. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Bortezomib may also make cancer cells more sensitive to radiation therapy. Giving samarium Sm 153 lexidronam pentasodium together with bortezomib may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of bortezomib when given together with samarium Sm 153 lexidronam pentasodium and to see how well they work in treating patients with relapsed or refractory multiple myeloma.
Key facts
- Study ID
- NCT00478075
- Run by
- Mayo Clinic
- People needed
- 50
- Starts
- 2005-09-01
- Expected to finish
- 2009-06-01
- Last updated by the study team
- 2011-05-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic Scottsdale — Scottsdale, Arizona, United States
- Mayo Clinic - Jacksonville — Jacksonville, Florida, United States
- Mayo Clinic Cancer Center — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.